cyclosporine has been researched along with pyrazines in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, MJ; Liu, ZM | 1 |
| Chen, S; Li, JW; Ma, SX; Wang, Y; Yan, YH | 1 |
| Chim, CS; Ooi, GC | 1 |
| Atanackovic, D; Ayuk, F; Kröger, N; Renges, H; Schieder, H; Zabelina, T; Zander, A | 1 |
| He, J; Liu, XL; Peng, WX; Song, J; Tang, J; Xu, P | 1 |
| Bergman, A; Chen, L; Cote, J; Dilzer, S; Herman, G; Krishna, R; Larson, P; Lasseter, K; Wagner, J; Wang, A; Zeng, W | 1 |
| Scheinfeld, N | 1 |
| Boccadoro, M; Bruno, B; Carnevale-Schianca, F; Corradini, P; Fanin, R; Giaccone, L; Guidi, S; Mattei, D; Milone, G; Montefusco, V; Patriarca, F; Peccatori, J; Petrucci, MT; Rotta, M; Sorasio, R | 1 |
| Adachi, D; Hattori, N; Nakamaki, T; Nakashima, H; Saito, B; Tomoyasu, S | 1 |
| Bernardi, P; Brancolini, C; Crivellato, E; Demarchi, F; Fontanini, A; Foti, C; Maestro, R; Potu, H | 1 |
| Ahn, BC; Bae, SA; Ha, JH; Jeon, YH; Lee, J; Lee, SW; Lee, YJ; Lee, YL; Yoon, GS | 1 |
| Nishi, S | 1 |
| Boenisch, O; Denecke, C; Khalpey, Z; Pratschke, J; Reutzel-Selke, A; Sawitzki, B; Seifert, M; Tullius, SG; Volk, HD | 1 |
| Gupta, S | 1 |
| Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D | 1 |
| McNeil, C | 1 |
| Alloway, RR; Cardi, MA; Krisl, JC; Shields, AR; Woodle, ES | 1 |
| Abedini, A; Abtahian, Z; Ashrafzadeh, M; Barati, S; Dastan, A; Dastan, F; Haseli, S; MohammadReza Hashemian, S; Sobhanian, A; Tabarsi, P; Yousefian, S | 1 |
3 review(s) available for cyclosporine and pyrazines
| Article | Year |
|---|---|
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Topics: Animals; Antineoplastic Agents; Benzoates; Boronic Acids; Bortezomib; Cyclosporine; Dasatinib; Deferasirox; Humans; Iron Chelating Agents; Ophthalmic Solutions; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Randomized Controlled Trials as Topic; Skin Diseases; Skin Neoplasms; Thiazoles; Triazoles | 2007 |
[Immunosuppressive agents in kidney transplantation].
Topics: Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cyclosporine; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Pyrazines; Rituximab; Sirolimus; Sphingosine; T-Lymphocytes; Tacrolimus; TOR Serine-Threonine Kinases | 2011 |
Immunotherapies in diabetes mellitus type 1.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Azathioprine; Basiliximab; Chaperonin 60; Cyclosporine; Daclizumab; Diabetes Mellitus, Type 1; Diet; Etanercept; Exenatide; Fatty Acids, Unsaturated; Glutamate Decarboxylase; Humans; Hypoglycemic Agents; Immunoconjugates; Immunoglobulin G; Immunosuppressive Agents; Insulin; Interferon-alpha; Interleukin 1 Receptor Antagonist Protein; Islets of Langerhans Transplantation; Niacinamide; Peptide Fragments; Peptides; Primary Prevention; Pyrazines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Rituximab; Secondary Prevention; Sitagliptin Phosphate; Tertiary Prevention; Triazoles; Venoms; Vitamin D; Vitamins | 2012 |
5 trial(s) available for cyclosporine and pyrazines
| Article | Year |
|---|---|
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; CD3 Complex; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Herpes Zoster; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Homologous | 2006 |
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
Topics: Adenosine Deaminase Inhibitors; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cyclosporine; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glycoproteins; Humans; Hypoglycemic Agents; Kidney; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclosporine; Drug Interactions; Humans; Immunosuppressive Agents; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Homologous | 2007 |
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2013 |
Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; COVID-19 Drug Treatment; Cyclosporine; Dexamethasone; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Intensive Care Units; Male; Middle Aged; Pandemics; Prospective Studies; Pyrazines; Respiration, Artificial; SARS-CoV-2; Treatment Outcome; Young Adult | 2021 |
10 other study(ies) available for cyclosporine and pyrazines
| Article | Year |
|---|---|
[Prevention of toxicity of cyclosporine A on rat pancreatic islet beta-cells by Ligustrazine].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Cyclosporine; Fibrinolytic Agents; Islets of Langerhans; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Thromboxane B2 | 1993 |
Effect of new thromboxane A2 synthesis inhibitor tetramethyl-pyrazine on pancreatic transplantation in diabetic rats.
Topics: Albuminuria; Animals; Benzofurans; beta 2-Microglobulin; Cyclosporine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inhibitors; Immunosuppressive Agents; Kidney; Organ Size; Pancreas Transplantation; Pyrazines; Rats; Rats, Wistar; Thromboxane A2; Thromboxane-A Synthase; Transplantation, Isogeneic | 1996 |
Bulbar palsy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Bulbar Palsy, Progressive; Combined Modality Therapy; Cranial Fossa, Posterior; Cranial Nerve Diseases; Cyclosporine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Immunoglobulin Light Chains; Immunosuppressive Agents; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pneumonia, Aspiration; Pyrazines; Reflex, Abnormal; Transplantation, Homologous; Vincristine | 2005 |
[The effect of tetramethylpyrazine on the pharmacokinetics of intragastrically administered cyclosporine A in rats].
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Calcium Channel Blockers; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Routes; Immunosuppressive Agents; Ligusticum; Male; Plants, Medicinal; Pyrazines; Random Allocation; Rats; Rats, Sprague-Dawley; Stomach; Verapamil | 2006 |
Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Cyclosporine; Dexamethasone; Drug Hypersensitivity; Exanthema Subitum; Herpesvirus 3, Human; Herpesvirus 6, Human; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Pyrazines; Syndrome; Virus Activation | 2009 |
The Isopeptidase Inhibitor G5 Triggers a Caspase-independent Necrotic Death in Cells Resistant to Apoptosis: A COMPARATIVE STUDY WITH THE PROTEASOME INHIBITOR BORTEZOMIB.
Topics: Actins; Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Boronic Acids; Bortezomib; Carbon-Nitrogen Lyases; Cell Adhesion; Cell Line, Transformed; Collagen; Cyclosporine; Cytoskeleton; Extracellular Matrix; Fibronectins; HMGB1 Protein; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Mice; Mice, Knockout; Necrosis; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrans; Pyrazines; Sulfhydryl Compounds | 2009 |
Evaluation of the reversal of multidrug resistance by MDR1 ribonucleic acid interference in a human colon cancer model using a Renilla luciferase reporter gene and coelenterazine.
Topics: Adenoviridae; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Colonic Neoplasms; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, Reporter; Humans; Imidazoles; Immunohistochemistry; Luciferases, Renilla; Luminescent Measurements; Mice; Models, Biological; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering | 2010 |
Low-dose cyclosporine mediates donor hyporesponsiveness in a fully mismatched rat kidney transplant model.
Topics: Adoptive Transfer; Animals; Antibodies; Boronic Acids; Bortezomib; Cyclosporine; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Transplantation; Proteasome Inhibitors; Pyrazines; Rats; T-Lymphocytes; T-Lymphocytes, Regulatory; Tissue Donors; Transplantation Conditioning | 2012 |
Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.
Topics: Acute Disease; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Cyclohexanes; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunosuppressive Agents; Maraviroc; Methotrexate; Pentostatin; Peripheral Blood Stem Cell Transplantation; Pyrazines; Quality of Life; Tacrolimus; Triazoles; Vorinostat | 2013 |
Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept.
Topics: Abatacept; Adult; Azathioprine; Biopsy; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Cyclosporine; Glomerulonephritis, IGA; Graft Rejection; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Male; Prednisone; Pyrazines; Treatment Outcome | 2014 |